Posted by Michael Wonder on 08 Jan 2024
'GSK's immunotherapy Jemperli paves way for second-line endometrial cancer treatment'
7 December 2023 - GSK's immunotherapy Jemperli (dostarlimab) is set to play a key role in the second-line treatment of patients with recurrent or advanced endometrial cancer who have run out of treatment options, a local expert said.
Following approval from the Ministry of Health and Welfare, Jemperli became eligible for being covered by health insurance on 1 December 2023.
